Artificial Intelligence driven Marketing Communications
NEW YORK, — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Arlo Technologies, Inc. (NYSE: ARLO)
Class Period: Investors who purchased shares pursuant and/or traceable to the Company’s Registration Statement and Prospectus issued in connection with the August 3, 2018 Initial Public Offering
Lead Plaintiff Deadline: March 25, 2019
The filed complaint alleges that the Registration Statement made materially false and/or misleading statements and/or failed to disclose that: (i) there was a flaw and/or quality issue with Arlo’s newly designed battery for its Ultra camera systems; (ii) this flaw and/or quality issue with the Ultra battery could result in a shipping delay of Arlo’s Ultra product; (iii) such a shipping delay endangered Arlo’s chances of launching the Ultra product in time for the crucial holiday season; (iv) such a shipping delay would allow Arlo’s competitors to capitalize on the Ultra product’s missed launch, thereby increasing their own market share; (v) Arlo’s consumers had been experiencing battery drain issues and other battery-related issues in connection with recent firmware updates; (vi) because of the foregoing, Arlo’s fourth quarter 2018 results and consumer base would be negatively impacted; and (vii) as a result, Arlo’s Registration Statement was materially false and misleading at all relevant times.
Get additional information about the ARLO lawsuit: http://www.kleinstocklaw.com/pslra-1/arlo-technologies-inc-loss-submission-form?wire=3
Activision Blizzard, Inc. (NASDAQ: ATVI)
Class Period: August 2, 2018 to January 10, 2019
Lead Plaintiff Deadline: March 19, 2019
The lawsuit alleges that throughout the class period, Activision Blizzard, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie’s partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies’ relationship would foreseeably have a significant negative impact on Activision Blizzard’s revenues; and (iii) as a result, Activision Blizzard’s public statements were materially false and misleading at all relevant times.
Get additional information about the ATVI lawsuit: http://www.kleinstocklaw.com/pslra-1/activision-blizzard-inc-loss-submission-form?wire=3
Micron Technology Inc. (NASDAQGS: MU)
Class Period: September 26, 2017 to November 19, 2018
Lead Plaintiff Deadline: March 25, 2019
Micron Technology Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company engaged in anti-competitive behavior, including artificially restricting supply growth of DRAM; (2) these anti-competitive efforts were reasonably likely to lead to regulatory scrutiny; (3) the Company’s anti-competitive efforts artificially boosted its operating metrics; (4) as a result, the Company’s financial performance, including revenue, was overstated; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Get additional information about the MU lawsuit: http://www.kleinstocklaw.com/pslra-1/micron-technology-inc-loss-submission-form?wire=3
Tyme Technologies, Inc. (NASDAQCM: TYME)
Class Period: March 14, 2018 to January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
The lawsuit alleges that throughout the class period, Tyme Technologies, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.
Get additional information about the TYME lawsuit: http://www.kleinstocklaw.com/pslra-1/tyme-technologies-inc-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.